Comparative efficacy and tolerability of amphotericin B lipid complex and liposomal amphotericin B in the treatment of invasive fungal infections in patients with hematological malignancies: literature review
https://doi.org/10.17650/1818-8346-2014-9-1-35-41
Abstract
An overview of the literature data concerning the comparison of toxicity, efficacy and cost of amphotericin B lipid complex and liposomal amphotericin B, as well as their comparison with amphotericin B deoxycholate are provided.
About the Authors
N. V. Dmitrieva
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences
Russian Federation
Laboratory for Microbiologic Diagnosis and Treatment of Infections in Oncology
Russian Federation
Laboratory for Microbiologic Diagnosis and Treatment of Infections in Oncology
I. N. Petukhova
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences
Russian Federation
Laboratory for Microbiologic Diagnosis and Treatment of Infections in Oncology
Russian Federation
Laboratory for Microbiologic Diagnosis and Treatment of Infections in Oncology
References
1. Pagona L., Caira M., Candoni A. et al. The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Hematologica 2006;91:1068–75.
2. Richardson M., Lass-Flörl C. Changing epidemiology of systemic fungal infections. Clin Microbiol Infect 2008;14(Suppl 4):5–24.
3. Morgan J., Wannenmuehler K.A., Marr K.A. et al. Incidence of invasive aspergillosis following hematopoietic stem cell and solid organ transplantation: interim results of a prospective multicenter surveillance program. Med Mycol 2005;43(Suppl 1):S49–58.
4. Rex J.H., Stevens D.A. Systemic antifungal agents. Chapter 40. In: Mandell, Douglas and Bennett`s Principles and Practice of Infectious Diseases, 7th edition. G.L. Mandell, J.E. Bennett, R. Dolin (eds.). Churchill Livingstone – Elsevier, 2010. Vol. 1, pp. 549–563.
5. Mehta J. Do variations in molecular structure affect the clinical efficacy and safety of lipid-based amphothericin B preparations? Leuk Res 1997;21:183–8.
6. Schlemmer F., Lagrange-Xelot M., Lacroix C. et al. Breakthrough Rhizopus infection on posaconazole prophylaxis following allogenic stem cell transplantation. Bone Marrow Transplant 2008;42:551–2.
7. Trifillo S., Singhal S., Williams S. et al. Breakthrough fungal infections after allogeneic hematoipoietic stem cell transplantation in patients on prophylactic voriconazole. Bone Marrow Transplant 2007;40:451–6.
8. Madureira A., Bergeron A., Lacroix C. et al. Breakthrough invasive aspergillosis in allogeneic hematopoietic stem cell transplant recepients treated with caspofungin. Int J Antimicrob Agents 2007;30:551–4.
9. Bowden R., Chandrasekar P., White M.H. et al. A double-blind, randomized, controlled trial of amphoithericin B colloidal dispersion versus amphothericin B for treatment of invasive aspergillosis in immunocompromised patients. Clin Infect Dis 2002;35:359–66.
10. Clark A.D., Mc Kendrick S., Tansey P.J. et al. A comparative analysis of lipidcomplexed and liposomal amphothericin B preparations in haematological oncology. Br J Haematol 1998;103:198–204.
11. Smith P.J., Olson J.A., Constable D. et al. Effects of dosing regimen on accumulation, retention and prophylactic efficacy of liposomal amphothericin B. J Antimicrob Chemother 2007;59:941–51.
12. Clark J.M., Whitney R.R., Olsen S.J. et al. Amphothericin B lipid complex therapy of experimental fungal infections in mice. Antimicrob Agents Chemother 1991;35:615–21.
13. Olson J.A., Adler-Moore J.P., Schwartz J. et al. Comparative efficacies, toxicities and tissue concentrations of amphothericin B lipid formulations in a murine pulmonary aspergillosis model. Antimicrob Agents Chemother 2006;50:2122–31.
14. Paterson P., Seaton S., Prentice H.G. et al. Treatment failure in invasive aspergillosis: susceptibility of deep tissue isolates following treatment with amphothericin B. J Antimicrob Chemother 2003;52:873–6.
15. Janoff A.S., Perkins W.R., Saletan S.L. et al. Amphothericin B lipid complex (ABLC™): a molecular rationale for the attenuation of amphothericin B related toxicities. J Liposome Res 1993;3:451–71.
16. Дмитриева Н.В., Петухова И.Н. Нежелательные явления, наблюдаемые при использовании современных противогрибковых препаратов в лечении инвазивных микозов. Онкогематология2013;2:47–60.
17. Dodds Ashley E., Lewis R., Lewis J. et al. Pharmacology of systemic antifungal agents. Clin Infect Dis 2006;43:28–39.
18. Sau K., Mambula S.S., Latz E. et al. The antifungal drug amphothericin B promotes inflammatory cytokine release by a toll-like receptor and CD14-dependent mechanism. J Biol Chem 2003;278:37561–8.
19. Malani P.N., Depestel D.D., Riddell J. et al. Experience with community-based amphothericin B infusion therapy. Pharmacotherapy 2005;25:690–7.
20. Craddock C., Anson J., Chu P. et al. Best practice guidelines for the management of adverse events associated with amphothericin B lipid complex. Expert Opin Drug Saf 2009;9:139–47.
21. Laniado-Laborin R., Cabrales-Vargas M.N. Amphothericin B: side effects and toxicity. Rev Iberoam Micol 2009;26(4): 223–7.
22. Klepser M. The value of amphothericin B in the treatment of invasive fungal infections. J Crit Care 2011;26:225–35.
23. Fisher M.A., Tailor G.H., Maislin G. et al. Risk factors for amphothericin B-associated nephrotoxicity. Am J Med 1989;87:547–52.
24. Wingard J.R., White M.H., Anassie E. et al. A randomized, double-blind comparative trial evaluating the safety of liposomal amphothericin B versus amphothericin B lipid complex in the empirical treatment of febrile neutropenia. Clin Infect Dis 2000;31:1155–63.
25. Olin J.L., Spooner L.M. Amphothericin Bassociated hyperbilirubinemia: case report and review of the literature. Pharmacotherapy 2006;26:1011–7.
26. Walsh T.J., Finberg R.W., Arndt C. et al. Liposomal amphothericin B for empirical therapy in patients with persistent fever and neutropenia. N Engl J Med 1999;340:764–71.
27. Mehta J., Blake J., Craddock C. Comparative efficacy of amphothericin B lipid complex and liposomal amphothericin B for the treatment of invasive fungal infections in HSCT recipients and other immunocompromised patient populations with hematologic malignancies: a critical review.
28. Open Transplant J 2011;5:23–9.
29. Slain D., Miller K., Khakoo R. et al. Infrequent occurrence of amphothericin B lipid omplexassociated nephrotoxicity in various clinical settings at a university hospital: a retrospective study. Clin Ther 2002;24(10):1636–42.
30. Deray G. Amphothericin B nephrotoxicity. J Antimicrob Chemother 2002;49(Suppl 1):37–41. 30. Andes D., Safdar N., Marchillo K., Conklin R. Pharmacokineticpharmacodynamic comparison of
31. amphothericin B (AMB) and two lipidassociated AMB preparations, liposomal AMB and AMB lipid complex, in murine candidiasis models. Antimicrob Agents Chemother 2006;50:674–84.
32. Wang J.L., Chang C.-H., Young-Xu Y., Chan K.A. Systematic review and metaanalysis of the tolerability and hepatotoxicity of antifungals in empirical and definitive therapy for invasive fungal infection. Antimicrob Agents Chemother 2010;54:2409–19.
33. Kleinberg M. What is the current and future status of conventional amphothericin B? Int J Antimicrob Agents 2006;26S:12–6.
34. Вarrett J.P., Vardulaki K.A., Conlon C. et al. A systematic review of the fungal effectiveness and tolerability of amphothericin B formulations. Clin Ther 2003;25:1295–320.
35. Cannon J.P., Garey K.W., Danziger L.H. A prospective and retrospectiuve analysis of the nephrotoxicity and efficacy of lipoid-based amphothericin B formulations. Pharmacotherapy 2001;21:1107–14.
36. Fleming R.V., Kantarjian H.M., Husni R. et al. Comparison of amphothericin B lipid complex (ABLC) vs. AmBisome in the treatment of suspected or documented fungal infections in patients with leukemia. Leuk Lymphoma 2001;40:511–20.
37. Mattiuzzi G.N., Kantrjian H., Faderi S. et al. Amphothericin B lipid complex as prophylaxis of invasive fungal infections in patients with acute myelogenous leukemia and myelodysplastic syndrome undergoing induction chemotherapy. Cancer 2004;100:581–9.
38. Wilson L.S., Reyes C.M., Stolpman M. et al. The direct cost and incidence of systemic fungal infections. Value Health 2002;5:26–34.
39. Martino R. Efficacy, safety and costeffectiveness of Amphothericin B Lipid Complex (ABLC): a review of the literature. Curr Med Res Opin 2004;20:485–504.
40. Kuti J.L., Kotapati S., Williams P. et al. Pharmacoeconomic analysis of amphothericin B lipid complex versus liposomal amphothericin B in the reatment of fungal infections. Pharmacoeconomics 2004;22:301–10.
Review
For citations:
Dmitrieva N.V., Petukhova I.N. Comparative efficacy and tolerability of amphotericin B lipid complex and liposomal amphotericin B in the treatment of invasive fungal infections in patients with hematological malignancies: literature review. Oncohematology. 2014;9(1):35-41. (In Russ.) https://doi.org/10.17650/1818-8346-2014-9-1-35-41
Views:
10513
Email this article 